Sónia Denise Ferreira Velho

Dr. Sónia Denise Ferreira Velho

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Gastric Cancer
Verified
Journal Article
Open access
CPCarolina Palmela
Carolina Palmela
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
LALisa Agostinho
Lisa Agostinho
FBFrancisco Branco
Francisco Branco
MSMarta Santos
Marta Santos
VBVickie E. Baracos
Vickie E. Baracos
Palmela C, et al. J Gastric Cancer. 2017 Mar;17:e8. https://doi.org/10.5230/jgc.2017.17.e8

1 October 2017 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
MCMarília L. Cravo
Marília L. Cravo
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
JTJoana Torres
Joana Torres
MSMaria Pia Costa Santos
Maria Pia Costa Santos
CPCarolina Palmela
Carolina Palmela
VBVickie Baracos
Vickie Baracos

1 February 2008 in Clinical Nutrition
Verified
Journal Article
Closed access
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
Pedro Marques-VidalPedro Marques-Vidal
Pedro Marques-Vidal
FBFátima Baptista
Fátima Baptista
MCMaria Ermelinda Camilo
Maria Ermelinda Camilo

1 January 2020 in Nutrition
Verified
Journal Article
Open access
MCMaria Pia Costa-Santos
Maria Pia Costa-Santos
CPCarolina Palmela
Carolina Palmela
JTJoana Torres
Joana Torres
AFAndreia Ferreira
Andreia Ferreira
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
MCMarília Cravo
Marília Cravo
The use of exclusive enteral nutrition (EEN) in patients with Crohn's disease (CD) before surgical resection can reduce disease activity and improve nutritional status. The mechanism of EEN action is unclear, but it might involve modulation of the intestinal microbiota. The aim of this study was to evaluate the effects (namely changes in gut microbiota) of preoperative EEN in adults with complicated CD referred to surgery. This was a prospective study of adult patients with CD referred to surgery. Patients with body mass index 10 %, serum albumin <3 g/dL, or a combination of some or all three, received EEN for ≥2 wk. The effects of EEN on clinical (Harvey-Bradshaw Index [HBI]) and laboratory markers (C-reactive protein [CRP], serum albumin, and fecal calprotectin) and fecal microbiota were analyzed after EEN (before surgery) and 6 mo later. We used 16 S rRNA gene sequencing to determine changes in the fecal microbiota. Fifteen patients were included, of whom 60% were men with a mean age of 45.4 ± 19.1 y. Of those, 10 received EEN. The median duration of preoperative EEN was 41.5 d (15-70 d). During EEN, there was a significant reduction in mean HBI (8.7 ± 1.9 versus 4.1 ± 2.4; P = 0.001) and CRP (11.7 ± 10.3 versus 0.8 ± 0.8 mg/dL; P = 0.008) and an increase in serum albumin (3.1 ± 0.6 versus 4 ± 0.6 g/dL; P = 0.022). Two patients did not require surgery after EEN. The overall microbial composition changed after EEN (Permutational analysis of variance test, P = 0.046) and there was a significant reduction in α diversity (8 ± 2.3 versus 5.2 ± 1.5; P = 0.023). EEN significantly changed the relative abundance of 11 taxonomic operational units (OTUs). At the family level, we found this was mainly due to the decrease in the Enterobacteriaceae family (7 OTUs). Six months after surgery, α diversity was not different from that before or after EEN; at this time point 6 OTUs were significantly different, mainly due to the decrease of Clostridiales order (3 OTUs). The incidence of postoperative complications and hospital length of stay were similar in EEN and immediate surgery groups, as well as clinical and endoscopic recurrence rates 6 mo after surgery. Preoperative EEN improved disease activity and nutritional status in patients with CD referred to surgery. Despite being malnourished, patients given EEN did not have increased postoperative complications compared with well-nourished patients. During EEN, overall microbiota composition changed and α diversity decreased. EEN did not influence postoperative recurrence and gut microbiota 6 mo after surgery.

19 May 2020 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
MSMaria Pia Costa Santos
Maria Pia Costa Santos
CCCátia Cunha
Cátia Cunha
LALisa Agostinho
Lisa Agostinho
RCRita Cruz
Rita Cruz
MCMarília Cravo
Marília Cravo
Introduction: Pancreatic surgery still carries a high morbidity and mortality even in specialized centers. The aim of this study was to evaluate the influence of patients’ body composition on postoperative complications and survival after pancreatic surgery. Methods: This was a retrospective study on patients undergoing pancreatic surgery between March 2012 and December 2017. Demographics, clinical data, and postoperative complications classified according to Clavien-Dindo were recorded. Body composition was assessed using routine diagnostic or staging computed tomography (CT). Multiple Cox proportional hazards models were adjusted. Results: Ninety patients were included, 55% were male, and the mean age was 68 ± 10.9 years. Of these 90, 92% had a total pancreatectomy or pancreaticoduodenectomy, 7% a distal pancreatectomy, and 1% a pancreaticoduodenectomy with multi-visceral resection; 84% had malignant disease. The incidence of major complications was 27.8% and the 90-day mortality was 8.8%. The ratio of visceral fat area/skeletal muscle area (VFA:SMA) was associated with an increased risk of complications (OR 2.24, 95% CI 1.14–4.87, p = 0.03) and 90-day survival (HR 2.13, 95% CI 1.13–4.01, p = 0.019). On simple analysis, shorter overall survival (OS) was observed in patients aged ≥70 years (p = 0.0009), with postoperative complications ≥IIIb (p = 0.01), an increased VFA:SMA (p = 0.007), and decreased muscle radiation attenuation (p = 1.6 × 10–5). In an OS model adjusted for age, disease malignancy, postoperative complications, and body composition parameters, muscle radiation attenuation remained significantly associated with survival (HR 0.94, 95% CI 0.90–0.98, p = 0.0016). A model which included only body composition variables had a discrimination ability (C-statistic 0.76) superior to a model which comprised conventional clinical variables (C-statistic 0.68). Conclusion: Body composition is a major determinant of postoperative complications and survival in pancreatic surgery patients.

1 January 2014 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
MCMarília Cravo
Marília Cravo
PFPaula A. Ferreira
Paula A. Ferreira
PSPatricia Sousa
Patricia Sousa
PMPaula Moura-Santos
Paula Moura-Santos
SVSónia Denise Ferreira Velho
Sónia Denise Ferreira Velho
Miguel BritoMiguel Brito
Miguel Brito
We aimed to identify the clinical and genetic [IL23 receptor (IL23R) single nucleotide polymorphisms (SNPs)] predictors of response to therapy in patients with ulcerative colitis. A total of 174 patients with ulcerative colitis, 99 women and 75 men, were included. The mean age of the patients was 47±15 years and the mean disease duration was 11±9 years. The number of patients classified as responders (R) or nonresponders (NR) to several therapies was as follows: 110 R and 53 NR to mesalazine (5-ASA), 28 R and 20 NR to azathioprine (AZT), 18 R and 7 NR to infliximab. Clinical and demographic variables were recorded. A total of four SNPs were studied: IL23R G1142A, C2370A, G43045A, and G9T. Genotyping was performed by real-time PCR using Taqman probes. Older patients were more prone to respond to 5-ASA (P=0.004), whereas those with pancolitis were less likely to respond to such therapies (P=0.002). Patients with extraintestinal manifestations (EIMs) were less likely to respond to 5-ASA (P=0.001), AZT (P=0.03), and corticosteroids (P=0.06). Carriers of the mutant allele for IL23R SNPs had a significantly higher probability of developing EIMs (P<0.05), a higher probability of being refractory to 5-ASA (P<0.03), but a higher likelihood of responding to AZT (P=0.05). A significant synergism was observed between IL23R C2370A and EIMs with respect to nonresponse to 5-ASA (P=0.03). Besides extent of disease and age at disease onset, the presence of EIMs may be a marker of refractoriness to 5-ASA, corticosteroids, and AZT. IL23R SNPs are associated both with EIMs and with nonresponse to 5-ASA and corticosteroids.